Lumosa Therapeutics Co., Ltd. (TPEX:6535)

Market Cap	28.64B -28.9%
Revenue (ttm)	42.59M +12.6%
Net Income	-433.41M
EPS	-2.61
Shares Out	168.46M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	202,252
Average Volume	207,738
Open	175.50
Previous Close	175.50
Day's Range	170.00 - 175.50
52-Week Range	122.00 - 329.50
Beta	0.11
RSI	35.07
Earnings Date	Mar 10, 2026

About Lumosa Therapeutics

Lumosa Therapeutics Co., Ltd., a clinical-stage pharmaceutical company, develops therapies and solutions for neurological and oncological diseases in Taiwan, Asia, the Americas, and Europe. The company offers Naldebain (LT – 1001), an analgesic injection for severe pain relief after surgery. It is developing LT3001, which is in Phase II clinical trial for the treatment of acute ischemic stroke; LT5001 that is in Phase Ib/II clinical trial for uremic pruritus; LT6001 that is in pre-clinical trials for neurological disorders; and CS028, which is ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 43
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6535

Financial Performance

In 2024, Lumosa Therapeutics's revenue was 39.15 million, a decrease of -31.21% compared to the previous year's 56.92 million. Losses were -424.78 million, 78.4% more than in 2023.